Abstract
Proliferative vitreoretinopathy (PVR) can occur in eyes with rhegmatogenous retinal detachment (RRD) or after RRD surgery, and it is the most common cause of failure of this surgery, accounting for about 75% of all primary failures. Complex biological pathways induce PVR development, with growth factors and cytokines from the vitreous and from the serum (as a result of the breakdown of the blood-retinal barrier) stimulating RPE and Muller cells transformation and proliferation, and membrane formation and contraction.
Identification of pre-operative risk factors, recognition of the early signs of PVR, use of adequate surgical techniques and of pharmacological therapy can reduce the PRV incidence.
Steroids can influence the inflammatory and proliferative components of PVR, by reducing the breakdown of the blood-retinal barrier, and the proliferation of Müller cell and of RPE cells. Some new formulation of intravitreal steroids are promising tool for the prevention of the PVR formation in eyes treated by vitreoretinal surgery.
Keywords: Intravitreal steroids, prevention, proliferative vitreoretinopathy, retinal detachment.
Current Pharmaceutical Design
Title:Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment
Volume: 21 Issue: 32
Author(s): Caterina Gagliano, Mario D. Toro, Teresio Avitabile, Santo Stella and Maurizio G. Uva
Affiliation:
Keywords: Intravitreal steroids, prevention, proliferative vitreoretinopathy, retinal detachment.
Abstract: Proliferative vitreoretinopathy (PVR) can occur in eyes with rhegmatogenous retinal detachment (RRD) or after RRD surgery, and it is the most common cause of failure of this surgery, accounting for about 75% of all primary failures. Complex biological pathways induce PVR development, with growth factors and cytokines from the vitreous and from the serum (as a result of the breakdown of the blood-retinal barrier) stimulating RPE and Muller cells transformation and proliferation, and membrane formation and contraction.
Identification of pre-operative risk factors, recognition of the early signs of PVR, use of adequate surgical techniques and of pharmacological therapy can reduce the PRV incidence.
Steroids can influence the inflammatory and proliferative components of PVR, by reducing the breakdown of the blood-retinal barrier, and the proliferation of Müller cell and of RPE cells. Some new formulation of intravitreal steroids are promising tool for the prevention of the PVR formation in eyes treated by vitreoretinal surgery.
Export Options
About this article
Cite this article as:
Gagliano Caterina, Toro D. Mario, Avitabile Teresio, Stella Santo and Uva G. Maurizio, Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909100212
DOI https://dx.doi.org/10.2174/1381612821666150909100212 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options
Current Diabetes Reviews Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders
Current Pharmaceutical Design Vascular Endothelial Growth Factor and Angiopoietins in Neurovascular Regeneration and Protection Following Stroke
Current Neurovascular Research Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Current Pharmaceutical Design Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Intravitreal Bevacizumab for Diabetic Retinopathy
Current Diabetes Reviews Central Retinal Vein Occlusion: Current Therapeutic Approach
Vascular Disease Prevention (Discontinued)